Acceptance of ivospemin (sbp-101) abstract for poster presentation at american association for cancer research (aacr)

Minneapolis, jan. 30, 2024 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for sbp-101, a proprietary polyamine analogue, has been accepted for poster presentation at the american association for cancer research (aacr), which will be held april 5-10, 2024. the work reflects the company's on-going collaboration with johns hopkins university school of medicine.
PBLA Ratings Summary
PBLA Quant Ranking